Abstracts tagged "Lupus"

Abstract Number: 2129 • 2018 ACR/ARHP Annual Meeting
Precipitating Anti-dsDNA Peptide Repertoires in Lupus
Jing Jing Wang¹, Alexander Colella¹, Dimitra Beroukas², Tim Chataway³ and Tom Gordon^1,4, ¹Immunology, Flinders University, Adelaide, Australia, ²Immunology, SA Pathology, Adelaide, AR, Australia, ³Proteomic Facility, Flinders University, Adelaide, Australia, ⁴Immunology, SA Pathology, Adelaide, Australia
Background/Purpose: Anti-double-stranded (ds)DNA autoantibodies are prototypic serological markers of systemic lupus erythematosus (SLE) but little is known about their immunoglobulin variable (IgV) region composition at…
Abstract Number: 2892 • 2018 ACR/ARHP Annual Meeting
Safety and Immune Response of a Live Attenuated Herpes Zoster Vaccine in Patients with Systemic Lupus Erythematosus (SLE): A Randomized Placebo-Controlled Trial
Chi Chiu Mok¹, Kwok Hung Chan², Ling Yin Ho³ and Patrick Chiu Yat Woo², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Microbiology, University of Hong Kong, Hong Kong, Hong Kong, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To evaluate the safety and immune response of a live attenuated herpes zoster (HZ) vaccine in patients with SLE by a randomized placebo-control trial…
Abstract Number: 474 • 2018 ACR/ARHP Annual Meeting
Lupus Impact Tracker (LIT) As a New Tool in Assessing Patient Reported Outcome in Pediatric Lupus
Suhas Ganguli¹, Joyce Hui-Yuen¹, Meenakshi Jolly^2,3, Jane Cerise⁴ and B. Anne Eberhard⁵, ¹Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ²Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Biostatistics, The Feinstein Institute for Medical Research, Manhasset, NY, ⁵Pediatric Rheumatology, Cohen Children's Medical Center, New Hyde Park, NY
Background/Purpose: Patient Reported Outcome (PRO) measures for Quality of Life (QoL) in patients with lupus are useful supplements to the physician-derived indices of disease activity…
Abstract Number: 939 • 2018 ACR/ARHP Annual Meeting
Rab4A Protects from Lupus Nephritis By Limiting Germinal Center Formation and Pro-Inflammatory Expression of GLUT1 and Integrin By Renal Epithelial Cells
Gourav Choudhary¹, Nick Huang², Ryan Kelly³, Thomas Winans⁴, Manuel Duarte², Mark Haas⁵ and Andras Perl², ¹Department of Biochemistry and Mol. Biology, SUNY Upstate Medical University, Syracuse, NY, ²Medicine, SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY, ⁴SUNY Upstate Medical University, Syracuse, NY, ⁵Professor of Pathology, Cedars-Sinai, Los Angeles, CA
Background/Purpose: Lupus nephritis is most common cause of mortality and morbidity in systemic lupus erythematosus (SLE) patients and 60% of SLE patients develops lupus nephritis.…
Abstract Number: 1874 • 2018 ACR/ARHP Annual Meeting
Remission and Low Disease Activity State Are Protective of Intermediate and Long-Term Outcomes in SLE Patients. Data from a Multi-Ethnic, Multi-Center US Cohort
Guillermo J. Pons-Estel^1,2, Graciela S. Alarcón³, Manuel Ugarte-Gil^4,5, Luis M. Vilá⁶, John D. Reveille⁷ and Gerald McGwin³, ¹Rheumatology, Hospital Provincial de Rosario, Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Universidad Científica del Sur, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁶Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁷McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Over the last few years the importance of treating patients with SLE towards achieving either Remission or LDAS (Treat-to-Target approach) has become evident. We…
Abstract Number: 2330 • 2018 ACR/ARHP Annual Meeting
Vitamin D and Bisphosphonate Therapy in SLE Patients Who Receive Glucocorticoids: Are We Offering the Best Care?
Smarika Sapkota¹, Sara Baig², Toy Hess³, Ann Marie O'Connell⁴, Jeremiah Menk³, Parastoo Fazeli⁵ and Anna K. Shmagel⁶, ¹Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, ²Department of Internal Medicine, University of Minnesota, Minneapolis, MN, ³University of Minnesota, Minneapolis, MN, ⁴University of Minnesota, Minnepolis, MN, ⁵Rheumatology, University of Minnesota, Minneapolis, MN, ⁶Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN
Background/Purpose: Glucocorticoids(GC) are frequently used for the treatment of systemic lupus erythematosus (SLE), and glucocorticoid induced osteoporosis (GIOP) is a well-known complication of long term…
Abstract Number: 2946 • 2018 ACR/ARHP Annual Meeting
T Peripheral Helper Cells Are Expanded in the Circulation of Active SLE Patients and Correlate with CD21low B Cells
Deepak Rao¹, Alexandra Bocharnikov², Chamith Fonseka³, Joshua Keegan², Betty Diamond⁴, Jennifer Anolik⁵, Peter Nigrovic¹, Soumya Raychaudhuri^3,6, James A. Lederer⁷ and Michael Brenner⁸, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Autoimmune Musculoskeletal and Hematopoietic Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute, Harvard University, Cambridge, MA, ⁷Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Pathologic T cell-B cell interactions and production of autoantibodies are hallmark features of SLE. T follicular helper (Tfh) cells are generally considered the principal…
Abstract Number: PP09 • 2018 ACR/ARHP Annual Meeting
Improved Quality of Life and Decreased Symptoms of Lupus with Diet, Exercise, and Functional Medicine
Marisa Zeppieri-Caruana, Lupus Chick, New York, NY
Background/Diagnosis: Like most people who live with a chronic illness and/or autoimmune disease, my story started long before I realized. Symptoms came and went throughout…
Abstract Number: 712 • 2018 ACR/ARHP Annual Meeting
Higher Prednisolone Dose during Treatment of Tuberculosis Correlates with Mortality during Tuberculosis Treatment in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study
Chiao-Feng Cheng, Cheng-Hsun Lu, Song-Chou Hsieh and Ko-Jen Li, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Tuberculosis (TB) has complex interplay with systemic lupus erythematosus (SLE). In addition, SLE, corticosteroid, and immunosuppressants are associated with TB infection. However, the prognostic…
Abstract Number: 972 • 2018 ACR/ARHP Annual Meeting
An Anti-CD28 Domain Antibody, Lulizumab, in Systemic Lupus Erythematosus: Results of a Phase II Study
Joan T. Merrill¹, Diane E. Shevell², Dominique Duchesne², Miroslawa Nowak², Sudeep Kundu², Ihab G. Girgis², Yanhua Sarah Hu², Steven G. Nadler³, Subhashis Banerjee² and John Throup², ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Bristol-Myers Squibb, Princeton, NJ, ³Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The T cell costimulatory molecule, CD28, is critical for the activation of pathogenic T cells in autoimmune diseases.1,2 An anti-CD28 domain antagonist antibody, lulizumab…
Abstract Number: 1888 • 2018 ACR/ARHP Annual Meeting
SLE Among the Leading Causes of Years of Potential Life Lost in Young Women: Population-Based Study, 2000-2015
Eric Yen and Ram R. Singh, UCLA, Los Angeles, CA
Background/Purpose: Ten-year survival of SLE has improved from <50% in the 1950s to ~95% in the 2000s. However, the relative and true disease burden for…
Abstract Number: 2356 • 2018 ACR/ARHP Annual Meeting
Perceptions, Incentives, and Barriers to Clinical Trial Participation: Qualitative Evaluation of Lupus Patients, Enriched for Minority Participants
Cristina Arriens¹, Fredonna Carthen², D'Angelo Grant², Paul Kamp¹, Stan Kamp¹, Katherine Thanou¹, Teresa Aberle¹, Eliza Chakravarty¹, Judith A. James³, Joan T. Merrill¹ and Motolani E. Ogunsanya⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, OKLAHOMA CITY, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials. This may lead to false, underpowered conclusions in race-based sub-group…
Abstract Number: 2959 • 2018 ACR/ARHP Annual Meeting
Development of a Set of Potentially Preventable Adverse Conditions Specific to Lupus: A Delphi Consensus Study
Candace H. Feldman¹, Cameron Speyer¹, Rachel Ashby², Bonnie L. Bermas³, Shamik Bhattacharyya⁴, Eliza Chakravarty⁵, Brendan Everett⁶, Elizabeth Ferucci⁷, Aimee O. Hersh⁸, Francisco Marty⁹, Joseph F. Merola¹⁰, Rosalind Ramsey-Goldman¹¹, Brad Rovin¹², Mary Beth Son¹³, Laura Tarter¹⁴, Sushrut Waikar¹⁵, Jinoos Yazdany¹⁶, Joel Weissman¹⁷ and Karen Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, UT Southwestern, Dallas, TX, ⁴Neurology, Brigham and Women's Hospital, Boston, MA, ⁵Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Cardiology, Brigham and Women's Hospital, Boston, MA, ⁷Alaska Native Medical Center, Anchorage, AK, ⁸Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁹Infectious Disease, Brigham and Women's Hospital, Boston, MA, ¹⁰Medicine, Rheumatology and Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹¹FSM, Northwestern University, Chicago, IL, ¹²Ohio State University Wexner Medical Center, Columbus, OH, ¹³Boston Children's Hospital, Harvard Medical School, Brookline, MA, ¹⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ¹⁵Renal, Brigham and Women's Hospital, Boston, MA, ¹⁶University of California, San Francisco, San Francisco, CA, ¹⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: The U.S. Agency for Healthcare Research and Quality developed a set of general ambulatory care-sensitive conditions that may result acute care use (hospitalizations and…
Abstract Number: 18 • 2018 ACR/ARHP Annual Meeting
Cytoplasmic FOXO1 Identifies Novel Disease-Activity Associated B Cell Subsets in SLE
Molly Hritzo¹ and Amit Golding², ¹Microbiology and Molecular Immunology, University of Maryland School of Medicine, Baltimore, MD, ²10 South Pine Street, Baltimore VA/VAMHCS AND University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: A key integrator of external stimuli in lymphocytes, Forkhead box protein O1 (FOXO1) is a highly attractive factor to study in SLE because it…
Abstract Number: 714 • 2018 ACR/ARHP Annual Meeting
A Predictive Clinical-Immunological Index for Infections Unveils Novel Innate and Adaptive Immunity Abnormalities As Key Risk Factors for Infections in a Cohort of Patients with Systemic Lupus Erythematosus
Diana Gómez-Martín^1,2, Jiram Torres-Ruíz³, Nancy R Mejía-Domínguez⁴, Guillermo Juárez-Vega⁵, Javier Merayo-Chalico³, Ana Barrera-Vargas³ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico city, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, ⁴Bioinformatics, Biostatistics and Computational Biology Unit, Red de Apoyo a la Investigación. Coordinación de la Investigación Científica, Universidad Nacional Autónoma de México, Mexico, Mexico, ⁵Flow Cytometry Unit, Red de Apoyo a la Investigación. Coordinación de la Investigación Científica, Universidad Nacional Autónoma de México, Mexico, Mexico
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have multiple innate and adaptive immune response abnormalities. It is unknown whether they play a key role in…

« Previous Page
1
…
5
6
7
8
9
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].